AgomAb Therapeutics (NASDAQ:AGMB) Director Buys 5,000 Shares of Company Stock

AgomAb Therapeutics NV (NASDAQ:AGMB) Director David Epstein bought 5,000 shares of the firm’s stock in a transaction on Tuesday, October 6th. The shares were acquired at an average cost of $8.70 per share, with a total value of $43,500.00. Following the purchase, the director directly owned 10,000 shares of the company’s stock, valued at approximately $87,000. This represents a 100.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

AgomAb Therapeutics Trading Up 1.7%

AGMB stock opened at $8.84 on Wednesday. The firm has a 50 day moving average price of $12.82 and a 200-day moving average price of $12.00. AgomAb Therapeutics NV has a 52-week low of $7.97 and a 52-week high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. Research analysts predict that AgomAb Therapeutics NV will post -1.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

AGMB has been the subject of several analyst reports. Piper Sandler initiated coverage on AgomAb Therapeutics in a report on Tuesday, August 25th. They set an “overweight” rating and a $60.00 price target for the company. B. Riley Financial assumed coverage on shares of AgomAb Therapeutics in a research note on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price target on the stock. Cantor Fitzgerald initiated coverage on shares of AgomAb Therapeutics in a research report on Wednesday, August 19th. They set an “overweight” rating on the stock. HC Wainwright restated a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday, September 16th. Finally, Wall Street Zen cut shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 27th. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.50.

AgomAb Therapeutics Company Profile

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab’s lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn’s disease.